MedTrace Logo

Prevention of Catheter-Related Bloodstream Infection in Patients With Haemato-Oncological Disease

NCT00207779 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2007-09-20

No results posted yet for this study

Summary

We, the researchers at Centre National de Greffe de Moelle Osseuse, have shown in a randomised study (in press), that a low dose of unfractionated heparin (100 IU/kg/daily) was safe and effective to prevent catheter-related bloodstream infection in patients with haemato-oncological disease.

The aim of this prospective randomised controlled trial is to compare the incidence of catheter-related bloodstream infection in 2 groups of patients with haemato-oncological disease:

* Group A: heparin impregnated catheters
* Group B: low-dose unfractionated heparin (100 IU/kg/daily)

Conditions

Interventions

DEVICE

heparin impregnated central venous catheters

Sponsors & Collaborators

  • Centre National de Greffe de Moelle Osseuse

    lead OTHER_GOV

Principal Investigators

  • Abderrahman Abdelkefi, MD · Centre National de Greffe de Moelle Osseuse

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2005-08-31

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00207779 on ClinicalTrials.gov